Pancreatic cancer remains a deadly disease with limited treatment options. In the first-line setting, the current standards of care (SOCs) are FOLFIRINOX and Celgene’s Abraxane, while in the second-line setting, Ipsen/Shire’s Onivyde is emerging as the SOC. Although current treatment is dominated by chemotherapies, upcoming targeted therapies including Halozyme Therapeutic’s PEGPH20, which targets the tumor’s microenvironment, are expected to provide more-efficacious and better-tolerated treatment options. The incidence of pancreatic neuroendocrine tumors (PNETs), which currently account for < 5% of pancreatic malignancies, is rising due to better diagnostics, but treatment remains limited—somatostatin analogue therapy remains the SOC. Few agents are in late-phase development for pancreatic cancer, but the early-phase pipeline is rich with novel targeted therapies.Questions answered: What size are the U.S., EU5, and Japanese pancreatic cancer and PNET drug-treatable patient populations, and how will drug-treatment rates change over the ten-year forecast period? How are patients with pancreatic cancer and PNETs treated in the markets under study? What are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled, and which needs will be addressed by the end of our forecast period? What are the key therapies in development for pancreatic cancer and PNETs? What sales/uptake could they secure in the pancreatic cancer market? What does the early-phase pipeline look like?Product Description:Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.